Left atrial appendage occlusion

Mohammad Kabir Haroon	China Medical University
Professor Bo Yu	(Department of Cardiovascular) The first hospital of China Medical University.
Ahmad Maqsuod Monsaf	China Medical University
Di Wu	China Medical University
Mohammad Sami	Xinjiang Medical University
Dawood Shah	China Medical University
Junaid Khan	China Medical University

Abstract

Background

One of the most important heart diseases is mitral stenosis (MS) that can due to left atrial and left atrial appendage clot. Blood clots in the left atrial appendage (LAA) can result in emboli, which can cause ischemia damage to the brain, kidneys, or other organs.

Objective

To determine the left atrial appendage occlusion

Methods

A cross-sectional study was conducted at a Global Medical Complex, Afghanistan, which was performed between September 2021 to July 2023, The total number of patients in our study were 100. The number of Male patients were 63 and female were 37. For all patients, we did diagnostic tests, BMI. We also took parameters of Diabetes , hypertension and coronary heart disease. We excluded pregnant women and children in our study. Data was tabulated and analyzed by SPSS version 25.

Result

In a current study total 100 patients were enrolled. The minimum age of patients were 61 years and the maximum age of the patients were 82 years. The mean age were 71.94 ± 5.726 years.

The minimum BMI of patients were 23 (Kg/m2) and the maximum BMI were 35 (Kg/m2) . The mean BMI were 28.55±3.740 (Kg/m2). The minimum Diameter of the Appendage of patients were 17 (mm) and the maximum Diameter of the Appendage were 34 (mm). The mean Diameter of Appendage were 25.94±5.705 (mm). P-values were < 0.05.

The frequency of type of appendage chicken wing were 24 and its percentage were 24%. The frequency of type of appendage cauliflower were 46 and its percentage were 46%. The frequency of type of appendage wingsockg were 30 and its percentage were 30%. The frequency of diagnostic test trans-oesophageal echocardiology (TEE) were 93 and its percentage were 93%. The frequency of diagnostic test Cardiac CT were 7 and its percentage were 7%.

The frequency of chest pain were present in 98 patients and its percentage were 98% and the frequency of chest pain were not present in 2 patients and its percentage were 2%.

Conclusion

We concluded that left arterial appendage occlusion (LAAO) is the best strategy for stroke reduction in old age people. The left arterial appendage occlusion (LAAO) procedure is more beneficial as compared to open surgery. Patients who have left arterial appendage have chest pain and hypertension. This type of disease is more common in old age people. In our study males were more as compared to females.

Keywords: Left arterial appendage occlusion (LAAO), left arterial appendage (LAA), Arterial fibrillation (AF).

Introduction

One of the most important heart diseases is mitral stenosis (MS) that can due to left atrial and left atrial appendage clot. Blood clots in the left atrial appendage (LAA) can result in emboli, which can cause ischemia damage to the brain, kidneys, or other organs supplied by the systemic circulation in 90% of cases of atrial fibrillation. One therapy approach to stop blood clots from forming in the left atrium is left atrial appendage occlusion.[1Treatment for left atrial appendage occlusion aims to stop blood clots from forming in the left atrium. The most prevalent cardiac arrhythmia that is clinically significant is atrial fibrillation (AF). The prevalence rises with age and is believed to be between 1% and 2% in the general population. Atrial fibrillation (AF), which has been linked to 15%–20% of all ischemic strokes, is strongly associated with stroke. [2,3,4] Stroke events are five times more common in patients with AF, and they also have higher rates of death, morbidity, and recurrence. There is variability in the temporal association between atrial fibrillation (AF) and stroke; some patients have AF at the time of stroke.[5] The LAA is a protrusion that resembles a finger that is next to the left atrium's (LA) main body. Most people consider it to be a skeletal trace of the original LA.[6] The procedure used a percutaneous transcatheter transseptal technique to remove LAA from the bloodstream.Furthermore, LAA blockage during coronary artery bypass grafting (CABG) was demonstrated by Healy et al. to be safe and effective in preventing stroke.[8] For patients unable to take oral anticoagulants due to recent or past bleeding, pregnancy, or other conditions, LAA occlusion may be an option.[9] This is especially true for the elderly, yet research suggests that anticoagulants may also be beneficial for them.[10] Despite LAA blockage, catheter-based methods were typically used.[11] During heart surgery, the left atrial appendix (LAA) can be readily removed, sutured, stapled, or ligated to remove it from the systemic circulation because it is the most prevalent site of thrombus formation in patients with atrial fibrillation (AF) and mitral stenosis (MS). The effectiveness of routine LAA occlusion in patients undergoing elective coronary artery bypass graft surgery is being assessed by the ongoing LAA occlusion study (LAAOS). The percutaneous LAA trans-catheter occlusion (PLAATO; Appriva Medical Inc.) and the WATCHMAN LAA system are two recently released devices that are specifically made for this purpose.[12] Transesophageal echocardiography (TEE) is currently used for every patient suspected of having a LAA clot because it is one of the best methods for identifying thrombus in LAA.[13] A TEE must be done prior to surgery in order to assess the degree of closure and the existence of blood clots. Nevertheless, AF sufferers lack this function, which significantly reduces their ability to empty their appendages. Virchow's triad-increased atrial fibrosis and dilatation typical of atrial fibrillation, enhanced blood coagulation, and stasis-underlies thrombus formation in atrial fibrillation. By removing or blocking the LAA, the appendage is kept out of the bloodstream, which inhibits the production of thrombi and, ultimately, embolization.[15,16, 14] OAC medication lowers the risk of stroke in people with AF and is advised for stroke prevention in AF patients who have risk factors.[17] A common description of the left atrial appendage is a little, ear-shaped protrusion of the left atrium's muscular wall. It is located anteriorly in the atrioventricular sulcus, adjacent to the pulmonary veins, phrenic nerve, and left circumflex artery.[18,19] The appendage has a capacity of around 9 mL and is 46 mm long.[20] It is commonly known that in individuals with nonvalvular AF, the LAA serves as the main location for thrombi to develop.[21]

MATERIALS AND METHODS

A cross-sectional study was conducted at a Global Medical Complex, Afghanistan, which was performed between September 2021 to July 2023, The total number of patients in our study were 100. The number of Male patients were 63 and female were 37. For all patients, we did diagnostic tests, BMI. We also took parameters of Diabetes , hypertension and coronary heart disease. We excluded pregnant women and children in our study. Data was tabulated and analyzed by SPSS version 25.

Results

	514 14			
Table 1: Mean age,	BMI and diameter	r of appendage of al	ll the enrolled	patients $(n=100)$

Variables	Minimum	Maximum	Mean <u>±</u> SD
Age (Years)	61	82	71.94±5.726
BMI (Kg/m2)	23	35	28.55±3.740
Diameter of Appendage (mm)	17	34	25.94±5.705

In a current study total 100 patients were enrolled. The minimum age of patients were 61 years and the maximum age of the patients were 82 years. The mean age were 71.94 ± 5.726 years.

The minimum BMI of patients were 23 (Kg/m2) and the maximum BMI were 35 (Kg/m2). The mean BMI were 28.55 ± 3.740 (Kg/m2). The minimum Diameter of the Appendage of patients were 17 (mm) and the maximum Diameter of the Appendage were 34 (mm). The mean Diameter of Appendage were 25.94 ± 5.705 (mm).

Table 2: Frequency and Percentage of Gender (n=100)				
Gender	Frequency	Percent	Valid Percent	Cumulative Percent
F	37	37.0	37.0	37.0
М	63	63.0	63.0	100.0
Total	100	100.0	100.0	
		-		

In the above table 2, the frequency of Female patients were 37 and the percentage were 37. The cumulative percent were same 37. The frequency of male patients were 63 and the percentage were 63. Total number of patients were 100 (100 %) in our study.



Figure 1: Bar chart of gender distribution.

In Figure 1, we did a gender distribution, we can see the male and female patient percentages in the above bar chart.

Table 3: Characteristics of enrolled patients (n=100)

Variables		
Chest Pain	Frequency	Percentage
NO	2	2.0
YES	98	98.0
Hypertension		
NO	19	19.0
YES	81	81.0
Diabetes		
NO	58	58.0
YES	42	42.0
Coronary artery		
disease		
NO	70	70.0
YES	30	30.0
Heart Failure		
NO	75	75.0
YES	25	25.0

Device used		
Amplatzer	14	14.0
Watchman	86	86.0
Type of Appendage		
Chicken wing	24	24.0
Cauliflower	46	46.0
Windsock	30	30.0
Diagnostic Test		
Cardiac CT	7	7.0
Trans-oesophageal echocardiology (TEE)	93	93.0

Patient characteristics of enrolled patients in table 3 were (n=100). The frequency of chest pain were present in 98 patients and its percentage were 98% and the frequency of chest pain were not present in 2 patients and its percentage were 2%. The frequency of hypertension were present in 81 patients and its percentage were 81% and the frequency of hypertension were not present in 19 patients and its percentage were 19%.

The frequency of diabetes were present in 42 patients and its percentage were 42% and the frequency of diabetes were not present in 58 patients and its percentage were 58%. The frequency of Coronary artery disease were present in 30 patients and its percentage were 30% and the frequency of Coronary artery disease were not present in 70 patients and its percentage were 70%.

The frequency of heart failure were present in 25patients and its percentage were 25% and the frequency of Coronary artery disease were not present in 75 patients and its percentage were 75%. The frequency of the watchman device were used 86 patients and its percentage were 86% and The frequency of the Amplatzer were used 14 patients and its percentage were 14%. P-values were < 0.05.

The frequency of type of appendage chicken wing were 24 and its percentage were 24%. The frequency of type of appendage cauliflower were 46 and its percentage were 46%. The frequency of type of appendage wingsockg were 30 and its percentage were 30%. The frequency of diagnostic test trans-oesophageal echocardiology (TEE) were 93 and its percentage were 93%. The frequency of diagnostic test Cardiac CT were 7 and its percentage were 7%.

Complications	Frequency	Percent	Valid Percent	Cumulative Percent
Pericardial Effusion	3	3.0	3.0	96.0
Thrombus Formation	4	4.0	4.0	100.0
Total	100	100.0	100.0	

Table 4: Complications of enrolled patients (n=100)

In the above table 4, the frequency of complications of pericardial effusion were 3 and the percentage were 3%. The cumulative percent were the same 3%. the frequency of complications of thrombus formation were 4 and the percentage were 4%. The cumulative percent were the same 4%. Total patients were enrolled 100.



Figure 2: Bar chart of Type of appendage.

In Figure 2, we can see the frequency of chicken wing, cauliflower, and wind sock. **Figure 3:** Bar chart of Devices used.

In Figure 3, we can see the percentage of watche man which is 86% and the percentage of Amplazer is 14 %. **Discussion**



Left arterial appendage (LAA) has a highly variable anatomical structure and may offer various procedural challenges. With more operator expertise and a lower risk of problems in the real-world scenario, recent studies are displaying encouraging outcomes. It is advisable to promote thorough patient evaluation before undertaking LAA closure. Patients with a high risk of procedural complications and overall prognosis should be able to be identified by this. Additionally, future clinical research and registries ought to keep advancing the design of LAA closure devices.[22] The Watchman device's long-term cost-effectiveness is amply demonstrated by available data. After four years, the cost-effectiveness of the LAAO is higher than that of the NOACs. As the usage of these devices grows, efforts should be made to develop strong clinical and financial models that will aid in our understanding of the long-term economic implications of these devices. [23–24] A few significant research are now underway that have the potential to alter the application and practice of LAAO. In August 2016, participants were randomly assigned 1:1 to either the Amulet device or the Watchman device in the Amplatzer Amulet LAA Occluder study (Amulet IDE), a prospective randomized multicenter global experiment. In patients with nonvalvular AF, the Amulet device's performance will be compared to that of the Watchman LAA closure device in order to assess its safety and effectiveness .[25] A composite of severe bleeding, all-cause death, or procedure-related complications through 12 months is the primary safety endpoint; a composite of ischemic stroke or systemic embolism through 18 months is the primary efficacy goal. Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients with Atrial Fibrillation is a significant ongoing clinical trial that is now accepting new participants. [26] A total of 400 patients are being recruited into the NOAC and LAAO (Watchman or Amulet) groups in this randomized multicenter open label experiment. The combination of stroke, another systemic cardiovascular event, clinically significant bleeding, cardiovascular death, or complications from the surgery or device is the main outcome.[27]

CONCLUSION

We concluded that left arterial appendage occlusion (LAAO) is the best strategy for stroke reduction in old age people. The left arterial appendage occlusion (LAAO) procedure is more beneficial as compared to open surgery. Patients who have left arterial appendage have chest pain and hypertension. This type of disease is more common in old age people. In our study males were more as compared to females.

References

[1] Parekh A, Jaladi R, Sharma S, Van Decker WA, Ezekowitz MD. Images in cardiovascular medicine. The case of a disappearing left atrial appendage thrombus: Direct visualization of left atrial thrombus migration, captured by echocardiography, in a patient with atrial fibrillation, resulting in a stroke. Circulation. 2006;114:e513–4.

[2] Noseworthy PA, Kaufman ES, Chen LY, Chung MK, Elkind MSV, Joglar JA, Leal MA, McCabe PJ, Pokorney SD, Yao X American Heart Association Council on Clinical Cardiology Electrocardiography and Arrhythmias Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association. Circulation. 2019;140:e944–63.

[3] January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140:e125–51.

[4] Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.

[5] Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte, Vardas P, Agewall S, Camm J, Baron Esquivias, Budts W, Carerj S, Casselman F, Coca A, De Caterina, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609–78.

[6] Beigel R, Wunderlich NC, Ho SY, Arsanjani R, Siegel RJ. The left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 2014; 7:1251–1265.

[7] Park JW, Leithäuser B, Rittger H, Brachmann J. Treatment strategies for prevention of cardio embolic stroke in atrial fibrillation. Clin Hemorheol Microcirc. 2010;46:251–64.

[8] Crystal E, Lamy A, Connolly SJ, Kleine P, Hohnloser SH, Semelhago L, et al. Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. Am Heart J. 2003;145:174–8.

[9] Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet. 2007;370:493–503.

[10] Schmidt H, Hammerstingl C, von der Recke G, Hardung D, Omran H. Long-term follow-up in patients with percutaneous left atrial appendage transcatheter occlusion system (PLAATO): Risk of thrombus formation and development of pulmonary venous obstruction after percutaneous left atrial appendage occlusion. J Am Coll Cardiol. 2006;47:36A.

[11] Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, et al. Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150:288–93.

[12] Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke. 2007;38:624–30.

[13] Mackensen GB, Swaminathan M, Mathew JP. PRO editorial: PRO: Three-dimensional transesophageal echocardiography is a major advance for intraoperative clinical management of patients undergoing cardiac surgery. Anesth Analg. 2010;110:1574–8.

[14] Healey JS, Crystal E, Lamy A, et al.Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005;150:288-93

[15] Fuster V, Rydén LE, Cannom DS, et al.ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030

[16] Hsu JC, Maddox TM, Kennedy KF, Katz DF, Marzec LN, Lubitz SA, Gehi AK, Turakhia MP, Marcus GM. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1:55–62.

[17] Holmes DR, Jr, Schwartz RS, Latus GG, Van Tassel RA. A History of Left Atrial Appendage Occlusion. Interv Cardiol Clin. 2018;7:143–50.

[18] Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S, Horton R, Sanchez JE, Bai R, Mohanty S, Pump A, Cereceda Brantes M, Gallinghouse GJ, Burkhardt JD, Cesarani F, Scaglione M, Natale A, Gaita F. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012 Aug 07;60(6):531-8.

[19] Wang Y, Di Biase L, Horton RP, Nguyen T, Morhanty P, Natale A. Left atrial appendage studied by computed tomography to help planning for appendage closure device placement. J Cardiovasc Electrophysiol. 2010 Sep;21(9):973-82.

[20] Di Biase L, Natale A, Romero J. Thrombogenic and Arrhythmogenic Roles of the Left Atrial Appendage in Atrial Fibrillation. Circulation. 2018 Oct 30;138(18):2036-2050.

[21] Majunke N, Sandri M, Adams V, Daehnert I, Mangner N, Schuler G, Moebius-Winkler S. Atrial and Brain Natriuretic Peptide Secretion After Percutaneous Closure of the Left Atrial Appendage With the Watchman Device. J Invasive Cardiol. 2015 Oct;27(10):448-52.

[22] Afzal MR, Kanmanthareddy A, Earnest M, et al. Impact of left atrial appendage exclusion using an epicardial ligation system (LARIAT) on atrial fibrillation burden in patients with cardiac implantable electronic devices. Heart Rhythm. 2015;12:52–59.

[23] Badhwar N, Lakkireddy D, Kawamura M, et al. Sequential percutaneous LAA ligation and pulmonary vein isolation in patients with persistent AF: initial results of a feasibility study. J Cardiovasc Electrophysiol. 2015;26:608–614.

[24] Lakkireddy D, Turagam M, Afzal MR, et al. Left atrial appendage closure and systemic homeostasis: the LAA HOMEOSTASIS study. J Am Coll Cardiol. 2018;71:135–144.

[25] AMPLATZERTM AmuletTM LAA Occluder trial (Amulet IDE) [Internet] Bethesda (MD): U.S. National Library of Medicine; 2018. [cited 2018 May 17].

[26] Cruz-Gonzalez I, Palazuelos Molinero J, Valenzuela M, et al. Brain natriuretic peptide levels variation after left atrial appendage occlusion. Catheter Cardiovasc Interv. 2016;87:E39–43.

[27] Left atrial appendage closure vs. novel anticoagulation agents in atrial fibrillation (PRAGUE-17) [Internet] Bethesda (MD): U.S. National Library of Medicine; 2016. [cited 2018 May 17].